Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012579 | 1.00 | CA1 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30961881 | 1.00 | CA1 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1275177 | 0.87 | TRPA1 (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL8148281 | 0.84 | CA1 (0.52) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11355733 | 0.83 | CA1 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL31098108 | 0.83 | CA1 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28880690 | 0.83 | CA1 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL6654063 | 0.83 | TRPA1 (0.48) | CA1CA2CA12CA9CA14 | |
| SCHEMBL353795 | 0.82 | VNN1 (0.40) | CA1CA2CA12CA7CA9 | |
| SCHEMBL4598114 | 0.81 | KDM4E (0.57) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577208-B2 | TEAD inhibitors and uses thereof | EHE Foundation (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| EP-4561998-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | Ratio Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119954725-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2025-04-24 | — | — | US | disclosed |
| EP-4541378-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-115427035-B | ENL/AF9 YEATS inhibitors | 洛克菲勒大学 | 2025-04-22 | — | — | CN | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2008049644-A1 | THYMIDINE ANALOGS FOR IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-02 | — | — | WO | disclosed |
| EP-1916003-A1 | Thymidine analogs for imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2008028688-A2 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008028688-A2 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
| EP-1897885-A1 | Compounds and methods for F labelled agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1897885-A1 | Compounds and methods for F labelled agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | ELI LILLY AND COMPANY (US) | 2006-10-19 | — | — | US | disclosed |
| EP-1597254-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | Eli Lilly and Company (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004111052-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE (MDR) | XENOVA LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004067529-A1 | INDOLE-DERIVATIVE MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | CA1 1229/4885CA2 1035/4885CA12 1417/4885 |
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | VHL, PC, NPC1 | CA1 965/4885CA2 3181/4885CA12 94/4885 |
| US-20260034252-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | CCR6, OGFRL1, IL6ST | CA1 1276/4885CA2 229/4885CA12 1489/4885 |
| US-12577208-B2 | TEAD inhibitors and uses thereof | BRCA1, BRAF, MEN1 | CA1 284/4885CA2 390/4885CA12 340/4885 |
| US-20060235222-A1 | Indole-derivative modulators of steroid hormone nuclear receptors | NR3C2, NR5A1, MC2R | CA1 3463/4885CA2 2019/4885CA12 3474/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | CA1 3577/4885CA2 3287/4885CA12 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.